Rosiglitazone → myocardial infarction — Null result

← All findings ⬇ Download signed audit packet

Ledger entry · null-result

Rosiglitazone → myocardial infarction — Null result

Drug: rosiglitazone · AE: myocardial infarction · vs pioglitazone

Caliper validation of the submitted claim (drug=rosiglitazone, AE=myocardial infarction, comparator=pioglitazone). BELOW_DEDUP_THRESHOLD — only 0 unique cases after dedup; insufficient signal density

Disproportionality

PRR: 49.7853033791773 (95% CI 7.01–353.44)
Yates χ²: 0
Cases (case-drug + AE): n = 0
Verdict: BELOW_DEDUP_THRESHOLD — only 0 unique cases after dedup; insufficient signal density

Top reactions in cohort

MedDRA PT	n
No reactions surfaced in cohort.

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: 2c0322078e007a2a063a994658f95ec941459820